IR-Med Inc. (IRME) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

IR-Med Inc. (IRME) Healthcare & Pipeline Overview

IR-Med Inc., based in Israel, develops non-invasive medical devices like PressureSafe and DiaSafe for early detection of pressure injuries and diabetic foot ulcers. With a small team and a focus on optical monitoring technology, the company targets unmet needs in healthcare settings.

What Is the Investment Thesis for IRME?

IR-Med Inc. presents a compelling investment thesis centered on its innovative non-invasive medical devices targeting significant unmet needs. The company's PressureSafe device addresses the costly and prevalent issue of pressure injuries, while DiaSafe targets diabetic foot ulcers, a major complication of diabetes. The potential for early detection and prevention offered by these devices could drive adoption and market penetration. A key value driver is the successful completion of clinical trials and subsequent regulatory approvals, particularly from the FDA. Upcoming milestones include the commercialization of PressureSafe and further development of DiaSafe and Nobiotics. However, the company's small size and limited financial resources pose risks to its ability to execute its development and commercialization plans. With a beta of 2.84, the stock demonstrates high volatility.

Based on FMP financials and quantitative analysis

IRME Key Highlights

IR-Med Inc. focuses on non-invasive medical devices for early detection of pressure injuries, diabetic foot ulcers, and middle ear infections.

• The company's PressureSafe device targets a significant market need in pressure injury prevention.
• DiaSafe aims to address the growing problem of diabetic foot ulcers through early detection.
• Nobiotics is being developed as an otoscope for immediate indication of middle ear infections in children.
• IR-Med Inc. is headquartered in Rosh Pinna, Israel, indicating a focus on international markets.

Who Are IRME's Competitors?

IRME is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IRME's Key Strengths?

Innovative non-invasive technology.

• Focus on early detection.
• Potential for cost savings in healthcare.
• Addressing unmet needs in pressure injury and diabetic foot ulcer prevention.

What Are IRME's Weaknesses?

Small company with limited resources.

• Dependence on regulatory approvals.
• Limited commercialization experience.
• Potential competition from larger medical device companies.

What Could Drive IRME Stock Higher?

Completion of clinical trials for PressureSafe and DiaSafe.

• Regulatory approvals from FDA and other agencies.
• Commercial launch of PressureSafe.
• Development of Nobiotics for middle ear infection detection.
• Strategic partnerships with healthcare providers and distributors.

What Are the Key Risks for IRME?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Delays in regulatory approvals.
• Competition from larger medical device companies.
• Limited financial resources to support development and commercialization.
• Dependence on key personnel.
• Uncertainty in healthcare reimbursement policies.

What Are the Growth Opportunities for IRME?

• Expansion of PressureSafe into Long-Term Care Facilities: The market for pressure injury prevention in long-term care facilities is substantial, driven by the high prevalence of bedsores among elderly and immobile patients. IR-Med can capitalize on this opportunity by targeting nursing homes and assisted living facilities with its PressureSafe device. Successful penetration into this market requires demonstrating the device's ease of use, cost-effectiveness, and ability to reduce the incidence of pressure injuries. The timeline for this growth opportunity is immediate, as the need for pressure injury prevention is ongoing.
• Commercialization of DiaSafe for Diabetic Foot Ulcer Prevention: Diabetic foot ulcers represent a significant healthcare burden, leading to amputations and reduced quality of life. IR-Med's DiaSafe device offers the potential for early detection and prevention of these ulcers. The company can pursue partnerships with diabetes clinics and podiatry practices to promote the adoption of DiaSafe. The market for diabetic foot ulcer prevention is growing, driven by the increasing prevalence of diabetes worldwide. The timeline for this growth opportunity is dependent on successful clinical trials and regulatory approvals.
• Development and Launch of Nobiotics for Pediatric Middle Ear Infections: Middle ear infections are a common ailment in children, often requiring multiple doctor visits and antibiotic prescriptions. IR-Med's Nobiotics device aims to provide physicians with immediate indications of middle ear infections, potentially reducing the need for unnecessary antibiotic use. The market for pediatric otoscopes is well-established, but Nobiotics' potential for improved diagnostic accuracy could give it a competitive edge. The timeline for this growth opportunity depends on successful product development and clinical validation.
• Strategic Partnerships with Healthcare Providers and Distributors: To accelerate market penetration and expand its reach, IR-Med can pursue strategic partnerships with healthcare providers, hospitals, and medical device distributors. These partnerships can provide access to established sales channels and customer networks. Collaborations with key opinion leaders and medical researchers can also enhance the company's credibility and promote the adoption of its devices. The timeline for this growth opportunity is ongoing, as building strong relationships with industry stakeholders is crucial for long-term success.
• Geographic Expansion into International Markets: While headquartered in Israel, IR-Med has the potential to expand its market reach into other international markets, including Europe and Asia. These markets offer significant growth opportunities, driven by aging populations, increasing healthcare spending, and the rising prevalence of chronic diseases. Successful geographic expansion requires adapting the company's products and marketing strategies to meet the specific needs and regulatory requirements of each market. The timeline for this growth opportunity is medium-term, as it involves significant investment and planning.

What Threats Does IRME Face?

• Regulatory hurdles and delays.
• Competition from established medical device companies.
• Technological obsolescence.
• Reimbursement challenges from healthcare payers.

What Are IRME's Competitive Advantages?

• Proprietary optical monitoring technology.
• Focus on specific unmet needs in healthcare.
• Potential for early detection and prevention.
• Intellectual property protection through patents.

What Does IRME Do?

IR-Med Inc., headquartered in Rosh Pinna, Israel, is a medical device company dedicated to the development of non-invasive monitoring solutions. The company's core mission revolves around creating innovative devices that enable early detection and prevention of various medical conditions, primarily through optical monitoring technology. Their flagship product, PressureSafe, is a handheld, skin-agnostic device designed to detect pressure injuries in patients at risk of developing bedsores due to prolonged pressure. DiaSafe, another key product in their pipeline, focuses on the early detection of diabetic foot ulcers, a common and serious complication for diabetic patients. Additionally, IR-Med is developing Nobiotics, an otoscope that aims to provide physicians with immediate indications of middle ear infections, particularly in children. Founded with the vision of improving patient outcomes through non-invasive diagnostics, IR-Med is committed to advancing medical technology and addressing critical healthcare needs. The company's focus on early detection and prevention aligns with the growing emphasis on proactive healthcare management and cost-effective solutions. With a small team, IR-Med is focused on bringing its innovative devices to market and making a positive impact on patient care.

What Products and Services Does IRME Offer?

• Develop non-invasive medical devices.
• Focus on early detection of medical conditions.
• Create handheld optical monitoring devices.
• Target pressure injuries with PressureSafe.
• Address diabetic foot ulcers with DiaSafe.
• Develop Nobiotics for middle ear infection detection.

How Does IRME Make Money?

• Develop and manufacture medical devices.
• Seek regulatory approvals for their devices.
• Commercialize and sell their products to healthcare providers.
• Potentially license or partner for distribution.

What Industry Does IRME Operate In?

The medical device industry is characterized by rapid innovation, stringent regulatory requirements, and intense competition. Companies like IR-Med operate within a landscape driven by technological advancements in diagnostics and monitoring. The market for non-invasive medical devices is expanding, fueled by the increasing prevalence of chronic diseases like diabetes and the growing emphasis on preventive care. The competitive landscape includes established medical device manufacturers and emerging technology companies. IR-Med's success will depend on its ability to secure regulatory approvals, demonstrate clinical efficacy, and effectively commercialize its products.

Who Are IRME's Key Customers?

• Hospitals and clinics.
• Long-term care facilities.
• Diabetes clinics.
• Physicians specializing in wound care.
• Pediatricians.

Return on equity for IR-Med Inc. stands at 372.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -81.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.

IR-Med Inc. (IRME) Valuation Context

Relative to its peer group, IRME's quantitative score of 44/100 is below the peer average of 65/100.

Company Profile

IR-Med Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Rosh Pinna, IL. The company is led by CEO Oded Bashan. IRME has traded publicly since 2021.

IR-Med Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Wall Street analysts project IR-Med Inc. revenue of about $30.9M for fiscal 2026, with EPS near $0.17.

IRME Financials

IRME Latest News

IRME Analyst Consensus

IRME MoonshotScore

IR-Med Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources